{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:03:49Z","timestamp":1790766229334,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.bj.2020.11.011","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T21:17:29Z","timestamp":1606252649000},"page":"7-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Neutralizing monoclonal antibodies for COVID-19 treatment and prevention"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1311-060X","authenticated-orcid":false,"given":"Juan Pablo","family":"Jaworski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bj.2020.11.011_bib1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(03)14630-2","article-title":"Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003","volume":"362","author":"Zhong","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.bj.2020.11.011_bib2","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2020.11.011_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2020.11.011_bib5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bj.2020.11.011_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib7","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bj.2020.11.011_bib8","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3201\/eid2606.200320","article-title":"Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality","volume":"26","author":"Wilson","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.bj.2020.11.011_bib9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","author":"He","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.bj.2020.11.011_bib10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(20)30260-9","article-title":"Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study","volume":"395","author":"Wu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bj.2020.11.011_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb6936","article-title":"Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing","volume":"368","author":"Ferretti","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib12","series-title":"COVID-19 map","author":"Johns Hopkins Coronavirus Resource","year":"2020"},{"key":"10.1016\/j.bj.2020.11.011_bib13","first-page":"e102","article-title":"Cardiovascular disease, drug therapy, and mortality in covid-19","volume":"382","author":"Mehra","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2020.11.011_bib14","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bj.2020.11.011_bib15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bj.2020.11.011_bib16","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/nsr\/nwaa041","article-title":"Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients","volume":"7","author":"Zhou","year":"2020","journal-title":"Natl Sci Rev"},{"key":"10.1016\/j.bj.2020.11.011_bib17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bj.2020.11.011_bib18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bj.2020.11.011_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.bj.2020.11.011_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bj.2020.11.011_bib22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","article-title":"Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study","volume":"20","author":"To","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bj.2020.11.011_bib24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.bj.2020.11.011_bib25","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bj.2020.11.011_bib26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.bj.2020.11.011_bib27","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe acute respiratory syndrome coronavirus 2\u2212Specific antibody responses in coronavirus disease patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.bj.2020.11.011_bib28","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/cid\/ciaa489","article-title":"Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Qu","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bj.2020.11.011_bib29","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.bj.2020.11.011_bib30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12931-020-01411-2","article-title":"Predictors of fatality including radiographic findings in adults with COVID-19","volume":"21","author":"Li","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.bj.2020.11.011_bib32","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bj.2020.11.011_bib33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.virol.2010.12.020","article-title":"Antibody-mediated neutralization of flaviviruses: a reductionist view","volume":"411","author":"Dowd","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.bj.2020.11.011_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1203\/PDR.0b013e3180686ce0","article-title":"Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple","volume":"62","author":"Polack","year":"2007","journal-title":"Pediatr Res"},{"key":"10.1016\/j.bj.2020.11.011_bib35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.20020781","article-title":"A role for immune complexes in enhanced respiratory syncytial virus disease","volume":"196","author":"Polack","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.bj.2020.11.011_bib36","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.bj.2020.11.011_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib38","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1126\/science.abc4776","article-title":"SARS-CoV-2 infection protects against rechallenge in rhesus macaques","volume":"369","author":"Chandrashekar","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib41","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.abc5343","article-title":"Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques","volume":"369","author":"Deng","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib42","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic Review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bj.2020.11.011_bib45","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bj.2020.11.011_bib46","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bj.2020.11.011_bib47","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","article-title":"Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies","volume":"182","author":"Barnes","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bj.2020.11.011_bib48","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41423-020-0426-7","article-title":"Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor","volume":"17","author":"Chen","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.bj.2020.11.011_bib49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bj.2020.11.011_bib50","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.cell.2020.05.041","article-title":"Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19","volume":"181","author":"Sempowski","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bj.2020.11.011_bib51","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib52","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.bj.2020.11.011_bib53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.chom.2020.06.010","article-title":"Neutralization of SARS-CoV-2 by destruction of the prefusion spike","volume":"28","author":"Huo","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bj.2020.11.011_bib54","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bj.2020.11.011_bib55","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib56","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1126\/science.abc7424","article-title":"Broad neutralization of SARS-related viruses by human monoclonal antibodies","volume":"369","author":"Wec","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib57","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","article-title":"Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bj.2020.11.011_bib58","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.immuni.2020.06.001","article-title":"Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation","volume":"53","author":"Seydoux","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.bj.2020.11.011_bib59","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-020-0998-x","article-title":"Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein","volume":"26","author":"Zost","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.bj.2020.11.011_bib60","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"6506","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib61","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib62","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib63","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib64","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1126\/science.abc5881","article-title":"Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody","volume":"369","author":"Lv","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib65","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib66","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib67","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1084\/jem.20151267","article-title":"The role of Fc\u2013Fc\u03b3R interactions in IgG-mediated microbial neutralization","volume":"212","author":"Bournazos","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.bj.2020.11.011_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000948","article-title":"A crucial role for infected-cell\/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy","volume":"6","author":"Michaud","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bj.2020.11.011_bib69","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/COH.0000000000000149","article-title":"Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life","volume":"10","author":"Boesch","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.bj.2020.11.011_bib70","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib71","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.bj.2020.11.011_bib72","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/d41587-020-00011-1","article-title":"Convalescent serum lines up as first-choice treatment for coronavirus","volume":"38","author":"Sheridan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bj.2020.11.011_bib73","article-title":"COVID-19 Research in brief: 4 April to 10 April","author":"Carvalho","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.bj.2020.11.011_bib74","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bj.2020.11.011_bib75","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2020.11.011_bib76","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib77","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bj.2020.11.011_bib78","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib79","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-binding-site antibody to HIV that evolved near-Pan neutralization breadth","volume":"45","author":"Huang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.bj.2020.11.011_bib80","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib81","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib82","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"Scheid","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bj.2020.11.011_bib83","doi-asserted-by":"crossref","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bj.2020.11.011_bib84","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib85","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.bj.2020.11.011_bib87","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2020.11.011_bib88","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib89","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1542\/peds.2014-1665","article-title":"Updated guidance for Palivizumab prophylaxis Among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"134","author":"Brady","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.bj.2020.11.011_bib90","first-page":"20160001","article-title":"Basis and statistical design of the passive HIV-1 antibody mediated prevention (AMP) test-of-concept efficacy trials","volume":";9","author":"Gilbert","year":"2017","journal-title":"Stat Commun Infect Dis"},{"key":"10.1016\/j.bj.2020.11.011_bib91","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1084\/jem.20132494","article-title":"Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques","volume":"211","author":"Shingai","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.bj.2020.11.011_bib92","doi-asserted-by":"crossref","first-page":"15859","DOI":"10.1073\/pnas.1213409109","article-title":"A mouse model for HIV-1 entry","volume":"109","author":"Pietzsch","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bj.2020.11.011_bib93","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/imr.12511","article-title":"Use of broadly neutralizing antibodies for HIV-1 prevention","volume":"275","author":"Pegu","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.bj.2020.11.011_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial","volume":"14","author":"Mayer","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.bj.2020.11.011_bib95","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in\u00a0vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bj.2020.11.011_bib96","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1097\/QAD.0000000000001199","article-title":"Reproducing SIV\u0394nef vaccine correlates of protection","volume":"30","author":"Voss","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.bj.2020.11.011_bib97","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.11.011_bib98","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose Nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2020.11.011_bib99","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nbt0905-1073","article-title":"Monoclonal antibody successes in the clinic","volume":"23","author":"Reichert","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bj.2020.11.011_bib100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bj.2020.11.011_bib101","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat Med"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417020302092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417020302092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:08:41Z","timestamp":1762420121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2319417020302092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2319417020302092"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2020.11.011","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralizing monoclonal antibodies for COVID-19 treatment and prevention","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2020.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Chang Gung University. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}